On SNY’s 3Q10 CC, CEO Chris Viehbacher and COO Hanspeter Spek openly ridiculed Amphastar’s desperation in resorting to suing the FDA. They evidently didn’t see the irony in their remarks.
Given the noise Amphastar has been making about alleged mistreatment by the FDA with respect to its Lovenox ANDA, one might think WPI would have chimed in at least once to express an opinion. They have not done so, however, which leads me to believe that WPI considers the Lovenox ANDA to be dead as a doorknob.
Market Data 
Markets 
AI
